ReviewFrontiers in pharmacology2025
Computational-aided drug design strategies for drug discovery and development against oral diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NADPH oxidases in immunometabolism and disease pathology: mechanistic networks, pollutant triggers, and therapeutic frontiers.Cellular & molecular immunology · 2026Review
- In Silico Identification of Dual-Action Compounds Targeting TLR2 andDentistry journal · 2026Article
- Rationally Engineered D-Amino Acid Peptide DT7-3 Combats Multidrug-ResistantMicroorganisms · 2026Article
- The Effect of Viniferin on Liver Cancer: Research Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral diseases, including dental caries, periodontitis, oral cancer, and mucosal infections, significantly impact overall health, underscoring the need for effective drug development. However, the discovery of novel oral drugs remains challenging due to complex disease mechanisms and limitations in traditional drug screening methods. Computer-aided drug design (CADD) has emerged as a powerful technology to accelerate drug discovery by improving efficiency and reducing costs. This review explores the application of CADD in the development of peptide-based drugs, small molecules, and plant extracts for oral diseases. It discusses CADD-associated antibacterial, anti-inflammatory, anticancer, and tissue regeneration therapies, highlighting available models, online tools, and successful case studies. Additionally, this review examines the intersection of CADD with natural product-based drug discovery, expanding therapeutic possibilities. While CADD enhances drug discovery, challenges such as mismatches in virtual screening and the need for experimental validation remain to be overcome. Despite these limitations, CADD is gaining traction in oral medicine, with the potential to revolutionize treatment strategies. This review aims to inspire further research and promote innovative therapeutic approaches to improve oral health and patient outcomes by summarizing recent advancements and emerging trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.